This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
For the Rev. Beth Stotts, death is a natural part of her ministry. A major aspect of her job is guiding her congregants through their most vulnerable moments from birth throughout life. The struggles she has seen in her community led her to seek more training to help people face death, and in 2022 she added another credential to her spiritual one: end-of-life doula.
Health care practitioners (HCPs), and patients too, are sounding the alarm on unnecessary barriers in the system that can negatively impact patients’ access to quality care according to a new survey of HCPs and patients. Specifically, HCPs raised concerns over how pharmacy benefit managers (PBMs) and insurers inappropriately use utilization management tools, like prior authorization, to deny or delay care, ultimately harming the patient and impacting patient access to care.
Reports of a new federal plan to study whether there’s a link between vaccines and autism could serve as an early test of the commitments Sen. Bill Cassidy (R-La.) said he received from Robert F. Kennedy Jr. in exchange for his support for RFK Jr.’s confirmation as Health and Human Services secretary. On Friday, multiple news outlets reported that the Centers for Disease Control and Prevention was planning the study.
Switzerland-based Tenthpin Management Consultants has announced the launch of Tenthpin AI Labs (TAIL) in Hyderabad, creating a Global Centre of Excellence for AI-driven transformation in the Life Sciences sector. TAIL aims to help pharmaceutical, MedTech, biotech, and research organisations differentiate between AI hype and real value. By leveraging India’s technology talent and Hyderabads position as a life sciences hub, Tenthpin seeks to accelerate AI adoption across the drug life cycle,
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
After a year of controversy and complaints, U.S. Sen. Elizabeth Warren (D-Mass.) is asking a federal watchdog to investigate GSK for replacing a popular asthma inhaler with a so-called authorized generic at a much higher price in order to avoid paying Medicaid rebates. In a letter sent Tuesday to the Office of Inspector General at the U.S. Department of Health and Human Services, Warren accused the company of “outrageous profiteering” because the maneuver cost Medicaid nearly $1 bi
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Methenamine Hippurate Tablets USP, 1 gram. The approved product is a generic equivalent of Hiprex Tablets, 1 gram, in the United States. Methenamine Hippurate tablets are indicated for the prophylactic or suppressive treatment of frequently recurring urinary tract infections where long-term therapy is required.
66
66
Signup to get articles personalized to your interests!
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Methenamine Hippurate Tablets USP, 1 gram. The approved product is a generic equivalent of Hiprex Tablets, 1 gram, in the United States. Methenamine Hippurate tablets are indicated for the prophylactic or suppressive treatment of frequently recurring urinary tract infections where long-term therapy is required.
LONDON — Looking to expand its obesity offerings, Roche on Wednesday said it had partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion in upfront cash. The Swiss pharma giant and the Danish biotech will now work together to develop Zealand’s drug candidate petrelintide, aiming to test it on its own and in combination with Roche’s experimental CT-388.
The number of medicines prescribed for ADHD rose by 8% in the last quarter of 2024, the latest NHS figures show. Between October and December there were 870,000 prescription items for ADHD in England, showing a continuing upward trend. The number of identified patients prescribed the medicines also increased by 6.1% to 248,000 compared with […] The post Further 8% increase in ADHD prescribing in last quarter of 2024 appeared first on The Pharmacist.
Tuesday marked the fifth anniversary of the World Health Organization declaring Covid-19 a global pandemic. For science writer Carl Zimmer, a columnist for the New York Times, covering Covid meant “watching [scientists] figuring out this disease in real time.” Notably, “there were a lot of mysteries about it. I was really struck as, as others were, by how strange it was that, that the just a fundamental question of how Covid spread was so unclear and was leading to so much a
The Unseen Heroes of Generic Drugs: Stability Testing 101 As a consumer, have you ever stopped to think about the rigorous process that goes into bringing a generic version of your favorite medication to market? It's not just a matter of copying a formula and slapping a new label on it. Behind the scenes, generic drug manufacturers are working tirelessly to ensure that their products are safe, effective, and identical to their branded counterparts.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, hope everyone is enjoying the warmer weather and longer days. Let’s get into the news today.
The American Conference Institutes 21st Annual Paragraph IV Disputes is scheduled to take place from April 29-30, 2025 at The Altman Building in New York, NY. Widely recognized as the industry gold standard, the conference unites leaders from brand-name and generic drug companies, alongside federal judges, the U.S. PTOs PTAB, the FTC, and the FDA, to tackle the critical legal, regulatory, and business issues shaping pharmaceutical patent litigation.
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Hello all, this is Allison DeAngelis, filling in for your Morning Rounds maven Theresa Gaffney.
The collaboration aims to explore this WEE1 kinase inhibitor for treating human papillomavirus + (HPV+) and HPV- HNSCC with specific genomic markers. As per the agreement, Aprea will provide the therapy for backing pre-clinical studies that could pave the way for future trials. The company is set to retain the therapys title, interest, and complete rights.
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
On March 3, 2025, Amneal announced FDA acceptance of its Biologics License Application (BLA) for two proposed denosumab biosimilars referencing Amgens PROLIA and XGEVA. According to Amneal, the FDA has set a target action date in Q4 2025. Denosumab is a RANK ligand (RANKL) inhibitor that is used to treat bone loss. As previously reported , mAbxience will develop and manufacture the two denosumab biosimilars, and Amneal will pursue regulatory approval and has exclusive commercialization rights in
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
The transaction includes Unloxcyt (cosibelimab-ipdl), which was approved by FDA in December 2024 for treatment of adults with cutaneous squamous cell carcinoma (cSCC).
Funded by investors such as Flagship and General Catalyst, the AI startup claims its platform will help scientists speed up the experimentation process.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content